Orgenesis Inc. Faces Nasdaq Delisting
Orgenesis Inc. has recently announced significant changes as it transitions from Nasdaq to OTC Markets. This decision comes after the company received a formal notification from Nasdaq Stock Market, indicating that its common stock would be delisted. This move stems from the conclusion of a review by the Nasdaq Hearings Panel which found that Orgenesis did not meet the necessary requirements for continued listing.
Reasons for Delisting
The decision to delist was influenced primarily by Orgenesis' failure to adhere to the minimum bid price requirement, as well as failing to meet the minimum stockholders’ equity requirements. Despite a strategic move involving a reverse stock split intended to help regain compliance, the company fell short. This reverse stock split, which occurred shortly before the delisting notification, brought down the total number of shares from approximately 47.7 million to 4.77 million.
Transition to OTC Markets
As trading on Nasdaq ceases, Orgenesis' stock is anticipated to begin trading on the OTC Markets under the ticker symbol 'ORGS'. This transformation marks a significant shift in the company's market presence. In a bid to improve its standing, Orgenesis has also applied to be quoted on the OTCQX, a more prestigious category within the OTC markets that prides itself on housing companies that fulfill stricter financial criteria.
Corporate Developments
Despite these challenges, Orgenesis is striving to ensure compliance with regulatory standards and intends to continue regular reporting to the U.S. Securities and Exchange Commission. The company remains committed to maintaining investor confidence and compliance throughout this transition.
Encouraging Therapy Results
In the midst of operational hurdles, Orgenesis has reported positive developments regarding its CD19 CAR-T therapy, known as ORG-101. This innovative treatment has demonstrated promising results in clinical trials for Acute Lymphoblastic Leukemia, showcasing high response rates among both adults and children. Such progress offers a glimmer of hope for the company as it navigates through a turbulent financial period.
Financial Challenges and Future Outlook
Financially, Orgenesis faced hefty challenges leading to the Nasdaq delisting. Publicly available data highlights the company's market capitalization, now sitting at $15.36 million, which categorizes it as a small-cap entity. Additionally, their reported revenue of $0.66 million over the previous year reflects a troubling decline of nearly 97%. Investors are understandably cautious, given that the company's expense levels are rising amidst a substantial debt burden.
Funding and Collaborations
In an effort to bolster its financial health, Orgenesis has secured a recent funding boost of $750,000 from investor Jacob Safier, bringing the total loan amount to $1 million. This influx of capital is critical for the company as it looks to ensure operational continuity and pursue further innovations.
Moreover, a launched joint venture with Harley Street Healthcare Group marks another significant milestone. This partnership aims to develop and commercialize wellness and longevity therapies on a global scale, with a notable commitment of $10 million over the next three years from HSHG.
Conclusion
While the delisting news presents a major obstacle for Orgenesis Inc., the company is actively pursuing avenues for recovery and growth. Their focus on innovative therapies and strategic partnerships highlights a commitment to overcoming current challenges. Investors and stakeholders should remain informed of the company’s progress as it continues to adapt to its new trading environment.
Frequently Asked Questions
What is the reason for Orgenesis Inc. being delisted from Nasdaq?
Orgenesis Inc. was delisted due to its inability to meet Nasdaq’s minimum bid price and stockholders’ equity requirements.
What will happen to Orgenesis’ stock after the delisting?
The company's stock will begin trading on the OTC Markets under the same ticker symbol 'ORGS'.
How is Orgenesis addressing its financial challenges?
Orgenesis has secured additional funding and is pursuing strategic partnerships to enhance its financial standing and support its ongoing operations.
What is the CD19 CAR-T therapy developed by Orgenesis?
CD19 CAR-T therapy, referred to as ORG-101, is an innovative treatment aimed at treating Acute Lymphoblastic Leukemia.
What steps is Orgenesis taking to comply with regulatory standards?
Orgenesis is committed to submitting periodic reports to the U.S. Securities and Exchange Commission to maintain compliance with regulatory standards.
